| A duty to describe: Better the devil you know than the devil you don’t SD Brown, D Furrow, DF Hill, JC Gable, LP Porter, WJ Jacobs Perspectives on Psychological Science 9 (6), 626-640, 2014 | 43 | 2014 |
| Revisiting mediation in the social and behavioral sciences AJ Figueredo, RA Garcia, TC De Baca, JC Gable, D Weise Journal of Methods and Measurement in the Social Sciences 4 (1), 1-19, 2013 | 41 | 2013 |
| Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis L Newton, AM DeLozier, PC Griffiths, JN Hill, S Hudgens, T Symonds, ... Journal of patient-reported outcomes 3, 1-12, 2019 | 40 | 2019 |
| Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials AX Zhu, RD Nipp, RS Finn, PR Galle, JM Llovet, JF Blanc, T Okusaka, ... ESMO open 5 (4), e000797, 2020 | 19 | 2020 |
| Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient … AX Zhu, RS Finn, PR Galle, JM Llovet, JF Blanc, T Okusaka, I Chau, ... Annals of Oncology 29, viii208, 2018 | 12 | 2018 |
| Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2-advanced breast cancer (ABC) who progressed on endocrine therapy. PA Kaufman, M Toi, P Neven, J Sohn, GL Price, Y Lin, M Boye, L Li, ... Journal of Clinical Oncology 36 (15_suppl), 1049-1049, 2018 | 9 | 2018 |
| Validity and interpretation of a skin pain numeric rating scale among adults and adolescents with atopic dermatitis L Humphrey, T Symonds, J Gable, L Abetz-Webb, JI Silverberg, P Griffiths, ... Value in Health 20 (9), A806, 2017 | 5 | 2017 |
| Early Environment Questionnaire CJ Black, JC Gable Unpublished manuscript, 2012 | 5 | 2012 |
| Treatment experiences with CDK4&6 inhibitors among women with metastatic breast cancer: a qualitative study JJ Stephenson, JC Gable, R Zincavage, GL Price, C Churchill, E Zhu, ... Patient preference and adherence, 2417-2429, 2021 | 3 | 2021 |
| Health-related quality of life in MONARCH 3: abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2-advanced breast cancer MP Goetz, S Johnston, M Martin, E Tokunaga, IH Park, J Huober, M Toi, ... CANCER RESEARCH 79 (4), 2019 | 3 | 2019 |
| Mixed methods evaluation of an itch numeric rating scale among adult and adolescent patients with atopic dermatitis L Humphrey, T Symonds, J Gable, L Abetz-Webb, JI Silverberg, P Griffiths, ... Value in Health 20 (9), A806, 2017 | 3 | 2017 |
| Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study ND Parikh, A Girvan, J Coulter, J Gable, JL Poon, S Kim, A Chatterjee, ... BMC cancer 23 (1), 66, 2023 | 2 | 2023 |
| Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome S Hudgens, J Ramage, M Kulke, E Bergsland, L Anthony, M Caplin, ... Journal of patient-reported outcomes 3 (1), 1-9, 2019 | 2 | 2019 |
| PCN366-Qualitative patient interviews to support the FACT Hepatobiliary Symptom Index-8 among patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein J Gable, D Ayer, A Girvan, L Bowman, P Abada, C Ervin, E Evans, D Cella Value in Health 21, S76, 2018 | 2 | 2018 |
| Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. S Hudgens, J Gable, MH Kulke, E Bergsland, LB Anthony, ME Caplin, ... Journal of Clinical Oncology 35 (15_suppl), e15132-e15132, 2017 | 2 | 2017 |
| Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome. S Hudgens, J Gable, MH Kulke, E Bergsland, LB Anthony, ME Caplin, ... Journal of Clinical Oncology 35 (4_suppl), 583-583, 2017 | 2 | 2017 |
| An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer E Lim, F Boyle, M Okera, S Loi, SS Goksu, G van Hal, SC Chapman, ... Breast Cancer Research and Treatment 195 (3), 275-287, 2022 | 1 | 2022 |
| PCN221 Treatment Patterns Including Adherence/Persistence with Cyclin-Dependent Kinase 4&6 Inhibitors (CDK4&6I) Among US Commercially Insured Women with Metastatic Breast … M Singhal, B Nepal, MJ Fisch, D Debono, M Grabner, JJ Stephenson, ... Value in Health 23, S462, 2020 | 1 | 2020 |
| Abstract P6-16-01: Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2-advanced breast cancer MP Goetz, S Johnston, M Martin, E Tokunaga, IH Park, J Huober, M Toi, ... Cancer Research 79 (4_Supplement), P6-16-01-P6-16-01, 2019 | 1 | 2019 |
| Abstract P2-08-66: Outcomes among metastatic breast cancer patients with characteristics that confer a less favorable prognosis K Saverno, G Cuyun Carter, R Dufour, G Price, L Li, A DeLuca, ... Cancer Research 79 (4_Supplement), P2-08-66-P2-08-66, 2019 | 1 | 2019 |
